x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

WolverHeme Happy Hour

Bernard Marini, Anthony Perissinotti, et al.

Welcome to WolverHeme Happy Hour! This is a podcast dedicated to all things hematology! We discuss new data, debate controversial therapies, and talk about new and exciting research. While we nerd out about data, we"ll have a few drinks! Disclaimer: The views and opinions expressed on this podcast are solely those of the podcasters and guests and do not reflect the views or opinions of our employers or other affiliations.

health & fitness medicine

All Episodes

00:52:20

ASH Pregaming - Myeloma Madness with Manni and Papa Heme

WolverHeme Happy Hour ·

2023/12/01

In this episode, Anthony and Bernie are joined by two very special guests - Dr. Aaron "Papa Heme" Goodman and Dr. Manni "Myeloma Man" Mohyuddin - to discuss the most interesting myeloma abstracts at the upcoming 2023 ASH meeting! Will any of these change practice? Listen to find out! Abstracts Discussed: https://ash.confex.com/ash/2023/webprogram/Paper188547.html https://ash.confex.com/ash/2023/webprogram/Paper181765.html

en

00:54:30

AML Maintenance Part 2: a metaMORPHOsis?

WolverHeme Happy Hour ·

2023/11/08

In the second portion of our two part-series on AML maintenance, Anthony and Bernie delve into the studies of post-transplant FLT3 inhibitor maintenance. We discuss the controversial MORPHO study of gilteritinib and whether these results will change practice! Sorafenib observational study: https://pubmed.ncbi.nlm.nih.gov/30809038/ SORMAIN (sorafenib): https://pubmed.ncbi.nlm.nih.gov/32673171/ Chinese Sorafenib Phase III: https://pubmed.ncbi.nlm.nih.gov/32791048/ RADIUS (midostaurin):

en

00:51:39

AML Maintenance Part 1: Set Your QUAZARs to Stun

WolverHeme Happy Hour ·

2023/10/25

In the first of a two part-series, Anthony and Bernie dive into the data surrounding maintenance therapies in AML. This episode focuses on maintenance therapy for patients ineligible for transplant, with a focus on oral azacitidine and the controversial QUAZAR study. Key References: QUAZAR AML-001: https://pubmed.ncbi.nlm.nih.gov/33369355/ QUAZAR Letter to the Editor: https://pubmed.ncbi.nlm.nih.gov/33789022/ ASH Abstract Data on impact of # of Consolidation Cycles:

en

01:39:13

Episode 17: The Hemophilia Eras Tour

WolverHeme Happy Hour ·

2023/08/23

In this episode, we are joined by classical hematology experts, Madeleine Ochs, PharmD, BCOP and Justin Arnall, PharmD, BCOP, to teach us hemophilia 101! In this T-Swift themed, episode, we discuss the history of hemophilia treatment (through the "eras") and how new agents may change the management of hemophilia patients.

en

00:37:41

Common Sense Oncology: Outcomes That Matter

WolverHeme Happy Hour ·

2023/08/01

In this episode, Anthony and Bernie chat with Chris Booth, MD, and Aaron "Papa Heme" Goodman, MD, to talk about the Common Sense Oncology movement! Join the Common Sense Oncology movement at this link (it's free!): https://commonsenseoncology.org/ Lancet Oncol paper: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00319-4/fulltext

en

00:49:29

All too well: the reality of leukemia treatment

WolverHeme Happy Hour ·

2023/06/08

In this episode, Anthony, Bernie, and Lydia are joined by a former patient, Madeline B, to talk about her ALL treatment journey. Drawing inspiration from Taylor Swift's upcoming concert and heartfelt ballad ("All Too Well"), this episode tackles some of the unique challenges, emotions, and considerations that come with helping adolescents and young adults (AYA) with treatment for acute leukemia. This is a must-listen for anyone taking care of AYA patients!

en

01:10:20

Episode 14: A Quantum Leap in AML Treatment?...

WolverHeme Happy Hour ·

2023/05/09

In this episode, Anthony and Bernie are joined once again by special guest and hematology expert, Dr. Dale Bixby, to discuss the recent publication of the QUANTUM-First study of quizartinib in newly diagnosed AML. Should this study change practice in FLT3-ITD+ AML? Have we made a "Quantum Leap" in the treatment of these patients? Listen for a fun-filled discussion of the data! Notable References: QUANTUM-First Study: https://pubmed.ncbi.nlm.nih.gov/37116523/ WolverHeme Episode 8

en

01:08:03

Episode 13: You get blinatumomab! You get blinatumomab!

WolverHeme Happy Hour ·

2023/02/24

Blinatumomab - it's Oprah's new favorite drug! On this episode, Anthony and Bernie are joined by special guests Dr. Lydia Benitez and Dr. Patrick Burke to discuss the ECOG1910 trial of blinatumomab in adult ALL. Is this trial practice changing? Listen and find out! ECOG1910 Late-Breaking Abstract: https://ash.confex.com/ash/2022/webprogram/Paper171751.html

en

00:58:28

Episode 12: Tinder for T Cells - Bispecifics in DLBCL

WolverHeme Happy Hour ·

2023/02/08

In this episode, we are joined by two lymphoma experts - Victoria Nachar, PharmD, BCOP and Tycel Phillips MD - to discuss the use of bispecific antibodies in Diffuse Large B-Cell Lymphoma (DLBCL)! Stay tuned for an exciting episode where we discuss the data, their possible role in therapy, and what questions and controversies remain. Relevant Articles: Review on Design of Bispecifics - https://pubmed.ncbi.nlm.nih.gov/25728220/ Epcoritamab - https://pubmed.ncbi.nlm.nih.gov/36548927/ Glofitamab -

en

00:52:30

Episode 11: "Olu the Drunk Snowman" - IDH inhibitors...

WolverHeme Happy Hour ·

2023/01/21

In this episode, we are joined by Dr. Jill Lykon, Clinical Pharmacist Specialist in Hematology at the University of Miami, to discuss the use of IDH inhibitors in relapsed/refractory AML. How do we choose between IDH inhibitors? Is "Olu" the new standard IDH inhibitor in R/R AML, or just the name of a drunk snowman? What about ivosidenib? Olutasidenib Phase I - Watts, et al. Lancet. 2023: https://pubmed.ncbi.nlm.nih.gov/36370742/ Olutasidenib Phase II ASH Abstract:

en

01:13:04

Episode 10: ASH Recap Part 2 - Papa Heme + WolverHeme

WolverHeme Happy Hour ·

2022/12/21

In this episode, we are joined by the legendary hematologist and rock star - Dr. Aaron Goodman - aka "Papa Heme"! We discuss which ASH abstracts might be practice changing and which simply don't make the cut. Stay tuned for an entertaining and very educational episode!

en

00:40:04

Episode 9: ASH Recap Part 1 - Dauno-Double Trouble

WolverHeme Happy Hour ·

2022/12/14

In this episode, Anthony and Bernie begin to recap some interesting studies presented at ASH, starting with a discussion the results of the "Dauno-Double" Trial. Should it change practice? Dauno-Double Trial: https://ash.confex.com/ash/2022/webprogram/Paper157126.html Dr. Todd Lee breaking down the non-inferiority numbers: https://twitter.com/DrToddLee/status/1600662377250586627?s=20&t=RdIhJJpMG-G_oPUSH2u2mw

en

01:22:13

Episode 8: Pulling the Goalie on FLT3 Inhibitor Use...

WolverHeme Happy Hour ·

2022/11/23

In this enlightening episode, Anthony and Bernie chat about FLT3+ AML with Dr. Dale Bixby, Clinical Professor and expert in leukemia at the University of Michigan. We use two clinical cases to take a deep dive into the biology and prognostic implications of FLT3+ AML, pitfalls and controversies of variant allele frequency and allelic ratio testing, and the data that informs the use of FLT3 inhibitors in AML. Watch out for some possibly heretical views! REFERENCES Schlenk and Dohner (Impact of AML

en

00:47:55

Episode (3+)7: Straight Outta Roswell - OG AML Data

WolverHeme Happy Hour ·

2022/10/07

Finally back from a much needed vacation, in this episode, Anthony and Bernie discuss some of the "OG" data and pharmacology behind key AML therapies.

en

01:15:43

Episode 6: Dr. StrangeDrug or: How I Learned to Stop...

WolverHeme Happy Hour ·

2022/07/21

In this episode, Bernie and Anthony do an in-depth dive into the pharmacology, toxicity management, and clinical conundrums with asparaginase therapy, including how and when to monitor asparaginase activity levels (per Papa Heme request!). For those who don't know (and maybe aren't as nerdy as we are), the title is a reference to the 1964 film Dr. Strangelove!

en

01:24:43

Episode 5: IDH Inhibitors in AML: not so AGILE

WolverHeme Happy Hour ·

2022/06/03

In this episode, Bernie Marini and Anthony Perissinotti chat with special guest Charles Foucar, MD, a hematology specialist and expert in the field. We discuss the controversial FDA approval of ivosidenib in combination with azacitidine in newly diagnosed IDH1+ AML, based on the results of the AGILE study: https://www.nejm.org/doi/full/10.1056/NEJMoa2117344

en

00:55:29

Episode 4: All Aboard the Oncology StewardSHIP

WolverHeme Happy Hour ·

2022/05/27

In this episode, Bernie Marini and Anthony Perissinotti are joined by two special guest hematology experts - Lydia Benitez, PharmD, BCOP, and Madeleine Ochs, PharmD, BCOP. Maddy and Lydia help us dive into the topic of Oncology Stewardship, including how we can incorporate Oncology Stewardship into practice to improve outcomes for patients. Learn more about Oncology Stewardship in AML patients in our hot off the press paper in Annals of Hematology, written by Maddy (first author), Lydia (senior

en

00:50:03

Episode 3.2: Ranting About Rituximab in Acute...

WolverHeme Happy Hour ·

2022/04/22

In part two of this two-part episode, Bernie Marini and Anthony Perissinotti discuss the use of rituximab in acute lymphoblastic leukemia (ALL), based on the recent publication of the UKALL14 study (Marks, et al. Lancet Haematol, 2022): https://pubmed.ncbi.nlm.nih.gov/35358441/. We also discuss the previously published GRAALL study that evaluated rituximab in ALL (Maury, et al. NEJM, 2016, https://pubmed.ncbi.nlm.nih.gov/27626518/), and what we can conclude from the literature to date. The data

en

00:46:59

Episode 3.1: History of Acute Lymphoblastic Leukemia...

WolverHeme Happy Hour ·

2022/04/22

In part one of a two-part episode, Bernie Marini and Anthony Perissinotti take a journey through the history of acute lymphoblastic leukemia treatment throughout the decades and explain how we got to our current standard of care treatment of ALL patients. In part 2 we tackle the UKALL14 study evaluating the addition of rituximab to acute lymphoblastic leukemia therapy. Some important historical articles that we reference: Nitrogen mustard therapy: https://pubmed.ncbi.nlm.nih.gov/20997191/

en

00:44:33

Episode 2: We Don't Talk About Rylaze

WolverHeme Happy Hour ·

2022/03/18

Bernie Marini and Anthony Perissinotti discuss asparaginase, the data (or lack thereof) behind the FDA approval of Rylaze (Erwinia asparaginase), and concerning trends regarding switches between asparaginase products in clinical practice!

en

41 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown